Glaxo Wellcome
Executive Summary
Firm discloses three R&D project terminations in shareholder materials for the Glaxo SmithKline merger. The company has discontinued development of the Phase III glycine antagonist GV150,526 for stroke, and GW275,919 for treatment of pain and inflammation. The company has also stopped development of a Phase II compound for migraine prophylaxis, GV196,771. Glaxo has a 75% share of the U.S. migraine market with Imitrex and Amerge, merger documents state